Depression in parkinsons disease part 2: Therapy and management;Depression beim idiopathischen Parkinson-Syndrom Teil 2: Therapie und Management

Fortschritte der Neurologie Psychiatrie

Volumn 78, Issue 8, 2010, Pages 456-467

  Storch, A ^a   Schneider, C ^a   Ebersbach, G ^b   Fuchs, G ^c   Jost, W H ^d   Odin, P ^e   Reifschneider, G ^f   Bauer, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen Parkinson   (Germany)

^c Neurologisches Krankenhaus   (Germany)

^d DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^e Klinikum Bremerhaven Reinkenheide   (Germany)

^f Neuro Centrum Odenwald   (Germany)

Author keywords

Antidepressants; Depression; Management; Non pharmacological treatment; Parkinsons disease; Therapy

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIBENZEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; REBOXETINE; ROPINIROLE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

DEPRESSION; DISEASE ASSOCIATION; ELECTROCONVULSIVE THERAPY; HYPERICUM PERFORATUM; PARKINSON DISEASE; PSYCHOEDUCATION; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW;

EID: 77955478298     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1245535     Document Type: Review

References (93)

1. Storch A, Ebersbach G, Fuchs G et al. Depression beim idiopathischen Parkinsonsyndrom. Teil 1: Epidemiologie, Pathophysiologie, Klinik und Diagnostik. Fortschr Neurol Psychiat 2008 76 715-724
2. Rub U, Del T K., Schultz C et al. Parkinsons disease: The thalamic components of the limbic loop are severely impaired by alpha-synuclein immunpositive inclusion body pathology. Neurobiol Aging 2002 23 245-254
3. Okun M S., Watts R L. Depression associated with Parkinsons disease: clinical features and treatment. Neurology 2002 58 S63-S70
4. Lieberman A. Managing the neuropsychiatric symptoms of Parkinsons disease. Neurology 1998 50 S33-S38; discussion S 44-S38
5. Poewe W, Luginger E. Depression in Parkinsons disease: impediments to recognition and treatment options. Neurology 1999 52 S2-S6
6. Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care World. J?Biol Psychiatry 2007 8 67-104
7. McDowell I, Newel C. Measuring health. A guide to rating scales and questionaires. 2nd ed. Oxford Oxford University Press 1996
8. Reiff J, Witt K, Deuschl G. Medikamentöse Therapie depressiver Störungen beim Morbus Parkinson. Akt Neurol 2005 32 77-85
9. Mayeux R. Depression in the patient with Parkinsons disease. J?Clin Psychiatry 1990 51 Suppl 20-23; discussion 24 25
10. Schrag A, Barone P, Brown R G. et al. Depression rating scales in Parkinsons disease: critique and recommendations. Mov Disord 2007 22 1077-1092
11. Lemke M R., Ceballos-Baumann A O. Depression bei Parkinson-Patienten. Dtsch Ärztebl 2002 99 2625-2631
12. Lemke M. Dopaminagonisten als Antidepressiva. Nervenarzt 2007 78 31-38
13. Heinz A. Psychopathologische Korrelate dopaminerger Dysfunktion bei alkoholabh?ngigen und schizophrenen Patienten. Nervenarzt 1999 70 399-407
14. Remy P, Doder M, Lees A et al. Depression in Parkinsons disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005 128 1314-1322
15. Rogers D, Costall B, Domeney A M. et al. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology 2000 151 91-97
16. Maj J, Rogoz Z, Skuza G et al. Antidepressant effects of pramipexole, a novel dopamine receptor antagonist. J?Neural Transm 1997 104 525-533 (Pubitemid 27379907)
17. Willner P, Lappas S, Cheeta S et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 1994 115 454-462
18. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997 12 7-14
19. Habermann-Little B. An analysis of the prevalence and etiology of depression in Parkinsons disease. J?Neurosci Nurs 1991 23 165-169
20. Cummings J L. Depression and Parkinsons disease: a review. Am J Psychiatry 1992 149 443-454
21. Birkmayer W. Deprenyl (selegiline) in the treatment of Parkinsons disease. Acta Neurol Scand Suppl 1983 95 103-105
22. Pahwa R, Stacy M A., Factor S A. et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007 68 1108-1115
23. Buchwald B, Angersbach D, Jost W H. Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy. Fortschr Neurol Psychiatr 2007 75 236-241
24. Corrigan M, Denahan A Q., Wright C E. et al. Comparison of pramipexole and placebo in patients with major depression. Depress Anxiety 2000 11 58-65
25. Zarate C, Payne J L., Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004 161 54-60
26. Moller J C., Oertel W H., Koster J et al. Long-term efficacy and safety of pramipexole in advanced Parkinsons disease: results from a European multicenter trial. Mov Disord 2005 20 602-610
27. Bxarone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinsons disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 9 573-580
28. Fernandez H H., Merello M. Pramipexole for depression and motor symptoms in Parkinsons disease: can we kill two birds with one stone? Lancet Neurol 2010 9 556-557
29. Veazey C, Aki S O., Cook K F. et al. Prevalence and treatment of depression in Parkinsons disease. J?Neuropsychiatry Clin Neurosci 2005 17 310-323
30. Andersen J, Aabro E, Gulmann N et al. Anti-depressive treatment in Parkinsons disease. A controlled trial of the effect of nortriptyline in patients with Parkinsons disease treated with L-DOPA. Acta Neurol Scand 1980 62 210-219
31. Laitinen L. Desipramine in treatment of Parkinsons disease. A placebo-controlled study. Acta Neurol Scand 1969 45 109-113
32. Strang R. Imipramine in treatment of parkinsonism: a double-blind placebo study. Br Med J 1965 2 33-34
33. Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinsons disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008 23 850-857
34. Menza M, DeFronzo Dobkin R, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009 72 886-892
35. Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinsons disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008 23 850-857
36. Okun M, Fernandez H H. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology 2009 72 868-869
37. Cummings J L., Masterman D L. Depression in patients with Parkinsons disease. Int J Geriatr Psychiatry 1999 14 711-718
38. Wermuth L, Sorensen P S., Timm S et al. Depression in idiopathic Parkinsons disea e treated with citalopram. Nord J Psychiatry 1998 52 163-169
39. Leentjens A F., Vreeling F W., Luijckx G J. et al. SSRIs in the treatment of depression in Parkinsons disease. Int J Geriatr Psychiatry 2003 18 552-554
40. Linazaroso G. Worsening of Parkinsons disease by citalopram Parkinsonism. Relat Disord 2000 6 111-113
41. Steur E N. Increase of Parkinson disability after fluoxetine medication. Neurology 1993 43 211-213
42. Montastruc J, Fabre N, Blin O et al. Does fluoxetine aggravate Parkinsons disease? A pilot prospective study. Mov Disord 1995 10 355-357
43. McCance-Katz E F., Marek K L., Price L H. Serotonergic dysfunction in depression associated with Parkinsons disease. Neurology 1992 42 1813-1814
44. Jimenez-Jimenez F J., Tejeiro J, Martinez-Junquera G et al. Parkinsonism exacerbated by paroxetine. Neurology 1994 44 2406
45. Tesei S, Antonini A, Canesi M et al. Tolerability of paroxetine in Parkinsons disease: a prospective study. Mov Disord 2000 15 986-989
46. Richard I, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinsons disease. Parkinson Study Group. Neurology 1997 48 1070-1077
47. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999 53 1154
48. Lemke M R. Effect of reboxetine on depression in Parkinsons disease patients. J?Clin Psychiatry 2002 63 300-304
49. Normann C, Hesslinger B, Frauenknecht S et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997 30 263-265
50. Goetz C G., Tanner C M., Klawans H L. Bupropion in Parkinsons disease. Neurology 1984 34 1092-1094
51. Takats A, Tarczy M, Simo M et al. Moclomemide/aurorix treatment in Parkinsons disease with depression. Abstracts of the 11th Symposium on Parkinsons disease, Rome, Italy. New trends in clinical neuropharmacology 1994 VIII 260
52. Chan-Palay V, Zetzsche T, Savaskan E. Moclobemide in depressed patients with Parkinsons disease. Clin Neuropharm 1992 15 217B
53. Jansen Steur E, Ballering L A. Moclobemide and selegeline in the treatment of depression in Parkinsons disease. J?Neurol Neurosurg Psychiatry 1997 63 547
54. Gimenez-Roldan S, Dobato J L., Mateo D. Treatment of depression in Parkinsons disease with moclobemide: A pilot open-label study. Parkinsonism Relat Disord 1997 3 219-225
55. Torun S et al. Moclobemide in depressed patients with Parkinsons disease. Abstracts of the First Congress of the European Federation of Neurological Societies 1995. Eur J Neurol 1995 2 92
56. Linde K, Berner M M., Kriston L. St Johns wort for major depression. Cochrane Database Syst Rev 2008 8 CD000448
57. Izzo A, Ernst E. Interactions between herbal medicines and prescibed drugs. Drugs 2001 61 2163-2175
58. Fawcett J. Lithium combination in acute and maintenance treatment in unipolar and bipolar depression. J?Clin Psychiatry 2003 64 32-37
59. Bauer M, Crossley N A., Gerber S et al. The acute antidepressive effects of lithium: from monotherapy to augmentation. In: Bauer M, Grof P, M?ller-Oerlinghausen ed, Lithium in neuropsychiatry a comprehensive guide: Abingdon: Informa Healthcare 2006 109-128
60. Brandt-Christensen M, Kvist K, Nilsson F M. et al. Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinsonian drugs: a pharmacoepidemiological study. J?Neurol Neurosurg Psychiatry 2006 77 781-783
61. Furukawa T A., Streiner D L., Young L T. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001
62. Furukawa T A., Streiner D L., Young L T. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev 2002
63. Valenstein M, Taylor K K., Austin K et al. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 2004 161 654-661
64. Macht M, Schwarz R, Ellgring H. Patterns of psychological problems in Parkinsons disease. Acta Neurol Scand 2005 111 95-101
65. Ellgring H, Seiler S, Nagel U et al. Psychosocial problems of Parkinson patients: approaches to assessment and treatment. Adv Neurol 1990 53 349-353
66. Oertel W, Ellgring H. Parkinsons disease medical education and psychosocial aspects. Patient Educ Couns 1995 26 71-79
67. Macht M, Ellgring H. Psychologische Intervention bei der Parkinson-Erkrankung. Ein Behandlungsmanual. Stuttgart Kohlhammer 2003
68. Brand S, Dodel R, Hautzinger M et al. Depression bei M. Parkinson. Diagnostik und Therapie. Nervenarzt 2007 78 715-727
69. Faber R, Trimble M R. Electroconvulsive therapy in Parkinsons disease and other movement disorders. Mov Disord 1991 6 293-303
70. Olanow C, Watts R L., Koller W C. An algorithm (decision tree) for the management of Parkinsons disease (2001): treatment guidelines. Neurology 2001 56 S1-S88
71. Andersen K, Balldin J, Gottfries C G. et al. A double-blind evaluation of electroconvulsive therapy in Parkinsons disease with on-off phenomena. Acta Neurol Scand 1987 76 191-199
72. Epstein C M., Evatt M L., Funk A et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Par insons disease. Clin Neurophysiol 2007 118 2189-2194
73. Wassermann E M., Lisanby S H. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin Neurophysiol 2001 112 1367-1377
74. Demet E M., Chicz-Demet A, Fallon J H. et al. Sleep deprivation therapy in depressive illness and Parkinsons disease. Prog Neuropsychopharmacol Biol Psychiatry 1999 23 753-784
75. Paus S, Schmitz-Hubsch T, Wullner U et al. Bright light therapy in Parkinsons disease: a pilot study. Mov Disord 2007 22 1495-1498
76. Marsh L, McDonald W M., Cummings J et al. Provisional diagnostic criteria for depression in Parkinsons disease: report of an NINDS/NIMH Work Group. Mov Disord 2006 21 148-158
77. Oertel W H., Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In ed Leitlinien für Diagnostik und Therapie in der Neurologie. 4.berarbeitete Auflage ed. Stuttgart Georg Thieme Verlag 2008
78. Hirschfeld R. Clinical importance of long-term antidepressant treatment. Br J Psychiatry 2001 42 S4-S8
79. Reimherr F, Amsterdam J D., Quitkin F M. et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998 155 1247-1253
80. Paykel E, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995 25 1171-1180
81. Sporn J, Ghaemi S N., Sambur M R. et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000 12 137-140
82. Perugi G, Toni C, Ruffolo G et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001 34 399-406
83. Lattanzi L, DellOsso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002 4 307-315
84. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinsons disease: a national multicentre prospective randomized study. Eur J Neurol 2003 10 399-406
85. Reichmann H, Brecht H M., Kraus P H. et al. Pramipexol in der Parkinson-Krankheit. Ergebnisse einer Anwendungsbeobachtung. Nervenarzt 2002 73 745-750
86. Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004 20 131-138
87. Goldberg J, Burdick K E., Endick C J. Preliminary, randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 161 564-566
88. Lemke M R., Brecht H M., Koester J et al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with pramipexole. J?Neuropsychiatry Clin Neurosci 2005 17 214-220
89. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease: a national multicenter parallel-group randomized study. J?Neurol 2006 253 601-607
90. Rabey J, Orlov E, Korczyn A D. Comparison of fluvoxamine versus amitriptyline for treatment of depression in parkinsons disease. Neurology 1996 46 A374
91. Simons J. Fluoxetine in Parkinsons disease. Mov Disord 1996 11 581-582
92. Ceravolo R, Nuti A, Piccinni A et al. Paroxetine in Parkinsons disease: effects on motor and depressive symptoms. Neurology 2000 55 1216-1218
93. Shulman L, Singer C, Liefert R. Therapeutic effects of sertraline in patients with Parkinsons disease. Mov Disord 1996 1 12